New Medical Director at Kayentis: Estelle Haenel take the lead
Kayentis, a global expert in electronic data capture for patients in clinical trials, helps sponsors and CROs bring simplicity, efficiency and quality to the collection of clinical trial data from both patients and sites.
Grenoble, France, September 3, 2019 – Kayentis, a global provider of eCOA (electronic Clinical Outcome Assessment) solutions for clinical trials, today announces the appointment of Estelle Haenel, PharmD and Ph.D, as medical director.
Ms. Haenel brings to Kayentis more than 25 years’ pharma industry experience, including 18 years in clinical science and operations, that she will use to consolidate the scientific expertise across the company’s broad range of therapeutic areas. As a priority, she will bring to the forefront of the company strategy the perspectives of patients, sites and customers. This guiding principle is aimed at improving overall patient engagement in clinical trials, thereby helping pharmas, biotechs and CROs better meet the increasing regulatory requirements for more data and more patient-centric studies. Her role includes facilitating both sites’ and patients’ adoption of eCOA solutions as these technologies have matured. Of note will be Kayentis’ new generation eCOA platform – Clin’form3 – designed to improve patient engagement, connection with medical devices and wearables, and BYOD implementation.
Ms. Haenel will also be Kayentis’ representative at the ePRO Consortium, enabling the company to have an active role in developing and implementing best practices in the eCOA field, as well as allowing Kayentis to share its experience and expertise via professional platforms.
“Kayentis is delighted to welcome Estelle,” said Guillaume Juge, CEO of Kayentis. “She brings extensive pharma industry experience and high-level skills that will consolidate our clinical knowledge, enhance our focus and reinforce the quality of care we provide to sites and patients. She will make a significant contribution to helping our customers across Europe, North America and Asia design and implement robust digital trial data collection studies.”
Kayentis focus on phases IIB/III and is increasingly extending its services towards late phase studies and Real-World Evidence (RWE). It has conducted digital data collection for over 200 clinical trials in 75 countries (9,000 sites and 70,000 patients) employing 90 different languages in a broad range of therapeutic areas: oncology, ophthalmology, dermatology, cardiovascular, immunology, pediatrics and neuroscience/CNS, among others.
“Kayentis’ growth has been impressive. This is due to the quality, energy and dedication of its teams,” said Estelle Haenel, medical director of Kayentis. “In its positioning as 100% eCOA-focused, it has specially trained staff fully dedicated to preparing, delivering and maintaining eCOA solutions for customers. I have confidence in Kayentis’ high-quality and innovative eCOA solutions to support efficient clinical trials. Given the current trends in the deployment of innovative technologies for patients, it is even more important to have young and flexible organizations devoted to, and experienced in, electronically collecting and managing patient data.”
During Ms Haenel’s more than 25-year career in the pharmaceutical industry, in pre-clinical and clinical research, she has worked for both biotech companies and big pharma, including Pfizer, which she joined in early 2012. She has led projects from phase 1 through 4 in multiple therapeutic areas and provided guidance and expertise in clinical science and clinical operations. She also has expertise in non-interventional clinical research and clinical pharmacology. Ms Haenel earned a PharmD from Paris V René Descartes University in 1994 and a Ph.D in Molecular and Cellular Biology from Paris Sud University in 2000. She has published several scientific papers.